v3.25.2
Segment Reporting - Schedule of Segment Loss Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting [Abstract]            
Navacaprant (NMRA-140) program $ (22,257)   $ (25,552)   $ (46,750) $ (49,871)
M4 PAM programs (2,370)   (1,278)   (5,252) (4,802)
NMRA-511 program (2,257)   (1,810)   (4,837) (3,697)
Preclinical programs (1,459)   (1,422)   (2,461) (3,831)
Research and development personnel-related costs (7,617)   (15,368)   (19,943) (26,243)
General and administrative expense (15,316)   (15,194)   (34,101) (29,511)
Interest income, net 1,814   5,271   4,888 11,636
Other segment items (3,269)   (3,347)   (12,267) (6,102)
Net loss $ (52,731) $ (67,992) $ (58,700) $ (53,721) $ (120,723) $ (112,421)